Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome
Recruitment status was: Recruiting
RATIONALE: Studying samples of cerebrospinal fluid from patients with cancer or meningeal syndrome may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial is studying cerebrospinal fluid samples in diagnosing carcinomatous meningitis in patients with cancer or meningeal syndrome.
|Brain and Central Nervous System Tumors Breast Cancer Metastatic Cancer||Other: diagnostic laboratory biomarker analysis Other: immunoenzyme technique Procedure: magnetic resonance imaging|
|Study Design:||Masking: None (Open Label)
Primary Purpose: Diagnostic
|Official Title:||Interest of the Dosage of CA 15-3 in CSF for Diagnosing Carcinomatous Meningitis in Breast Cancer|
- CA 15-3 levels in cerebrospinal fluid
|Study Start Date:||April 2008|
|Estimated Primary Completion Date:||May 2009 (Final data collection date for primary outcome measure)|
- Evaluate the validity of determining CA 15-3 levels in the cerebrospinal fluid (CSF) using automated immuno-enzymatic methods.
- Determine the sensitivity and specificity of these assays in assessing CA 15-3 in CSF.
- Assess favorability of intrathecal production of CA 15-3.
- Determine threshold interpretations of CA 15-3 levels in CSF.
OUTLINE: This is a multicenter study.
Within 15 days of suspected meningeal involvement, blood and cerebrospinal fluid samples are collected. Samples are examined by immunoenzyme assays. Patients with suspected cases of carcinomatous meningitis undergo cerebrospinal MRI.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00938756
|Centre Oscar Lambret||Recruiting|
|Lille, France, 59020|
|Contact: Emilie Le Rhun 33-32-029-5959|
|Principal Investigator:||Emilie Le Rhun||Centre Oscar Lambret|